

Virological assessment of hospitalized patients with COVID-2019

<https://doi.org/10.1038/s41586-020-2196-x>

Received: 1 March 2020

Accepted: 24 March 2020

Published online: 1 April 2020

 Check for updates

Roman Wölfel^{1,6}, Victor M. Corman^{2,6}, Wolfgang Guggemos^{3,6}, Michael Seilmaier³, Sabine Zange¹, Marcel A. Müller², Daniela Niemeyer², Terry C. Jones^{2,4}, Patrick Vollmar¹, Camilla Rothe⁵, Michael Hoelscher⁵, Tobias Bleicker², Sebastian Brünink², Julia Schneider², Rosina Ehmann¹, Katrin Zwirgmaier¹, Christian Drosten^{2,7} & Clemens Wendtner^{3,7}✉

Coronavirus disease 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in late 2019^{1,2}. Initial outbreaks in China involved 13.8% of cases with severe courses, and 6.1% of cases with critical courses³. This severe presentation may result from the virus using a virus receptor that is expressed predominantly in the lung^{2,4}; the same receptor tropism is thought to have determined the pathogenicity—but also aided in the control—of severe acute respiratory syndrome (SARS) in 2003⁵. However, there are reports of cases of COVID-19 in which the patient shows mild upper respiratory tract symptoms, which suggests the potential for pre- or oligosymptomatic transmission^{6–8}. There is an urgent need for information on virus replication, immunity and infectivity in specific sites of the body. Here we report a detailed virological analysis of nine cases of COVID-19 that provides proof of active virus replication in tissues of the upper respiratory tract. Pharyngeal virus shedding was very high during the first week of symptoms, with a peak at 7.11×10^8 RNA copies per throat swab on day 4. Infectious virus was readily isolated from samples derived from the throat or lung, but not from stool samples—in spite of high concentrations of virus RNA. Blood and urine samples never yielded virus. Active replication in the throat was confirmed by the presence of viral replicative RNA intermediates in the throat samples. We consistently detected sequence-distinct virus populations in throat and lung samples from one patient, proving independent replication. The shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 7 days in 50% of patients (and by day 14 in all patients), but was not followed by a rapid decline in viral load. COVID-19 can present as a mild illness of the upper respiratory tract. The confirmation of active virus replication in the upper respiratory tract has implications for the containment of COVID-19.

There is a close genetic relationship between SARS coronavirus (SARS-CoV) and the causative agent of COVID-19, SARS-CoV-2. The predominant expression of ACE2 in the lower respiratory tract is believed to have determined the natural history of SARS as an infection of the lower respiratory tract⁵. Although the positive detection of SARS-CoV-2 in clinical specimens from the upper respiratory tract has previously been described^{9,10}, these observations do not address the principal differences between SARS and COVID-19 in terms of clinical pathology. The patients who were studied here were enrolled because they acquired their infections upon known close contact to an index case, thereby avoiding representational biases owing to symptom-based case definitions. All patients were treated in a single hospital in Munich, Germany. Virological testing was done by two closely collaborating laboratories that used the same standards of technology for PCR with reverse transcription (RT-PCR) and virus isolation; these two laboratories confirmed each other's

results in almost all of the individual samples. Owing to the extremely high congruence of results, all data—except for the serological data (which are based on results from one laboratory only)—are presented together. The patients are part of a larger cluster of epidemiologically linked cases that occurred after 23 January 2020 in Munich, as discovered on 27 January (ref. ¹¹). The present study uses samples taken during the clinical course in the hospital, as well as from initial diagnostic testing before admission. In cases in which this initial diagnostic testing was done by other laboratories, the original samples were retrieved and retested under the rigorous quality standards of the present study.

RT-PCR, replication sites and infectivity

To first understand whether the described clinical presentations are solely caused by infection with SARS-CoV-2, samples from all patients

¹Bundeswehr Institute of Microbiology, Munich, Germany. ²Charité Universitätsmedizin Berlin, Berlin, Germany. ³Klinikum München-Schwabing, Munich, Germany. ⁴Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UK. ⁵University Hospital LMU Munich, Munich, Germany. ⁶These authors contributed equally: Roman Wölfel, Victor M. Corman, Wolfgang Guggemos. ⁷These authors jointly supervised this work: Christian Drosten, Clemens Wendtner. ✉e-mail: christian.drosten@charite.de; clemens.wendtner@muenchen-klinik.de




Fig. 1 | Hallmarks of viral shedding in aggregated samples. **a**, Samples and sample types per day. **b**, Viral RNA concentrations in samples from the upper respiratory tract. Neg., sample negative for RNA copies. **c**, Viral RNA concentrations in sputum and stool samples. **d**, Seroconversion and virus isolation success, dependent on day after the onset of symptoms. Top, fraction of seroconverted patients. Bottom, aggregated results of virus isolation trials. **e**, Virus isolation success, dependent on viral load. Viral loads were projected to RNA copies per ml (for sputum samples), per swab (for throat swab samples) or per g (for stool samples). **f, g**, Projected virus isolation success based on probit distributions. The inner lines are probit curves (dose–response rule). The outer dotted lines are 95% confidence interval. For a <5% isolation success, the estimated day was 9.78 (95% confidence interval 8.45–21.78) days after the onset of symptoms, and the estimated RNA concentration for <5% isolation success was estimated to be 5.40 log₁₀(RNA copies per ml) (95% confidence interval –4.11–6.51). **h**, Subgenomic viral RNA transcripts in relation to viral genomic RNA. Dots represent mean values of RT–PCR data obtained from at least two independent experiments on samples from individual patients. Plots show median values with interquartile ranges.

were tested against a panel of typical agents of respiratory viral infection, including human coronavirus (HCoV)-HKU1, HCoV-OC43, HCoV-NL63 and HCoV-229E, influenza virus A, influenza virus B, phinovirus, enterovirus, respiratory syncytial virus, human parainfluenza viruses 1–4, human metapneumovirus, adenovirus and human bocavirus. No coinfection was detected in any patient.

All patients were initially diagnosed by RT–PCR from oro- or nasopharyngeal swab specimens¹². Both types of specimen were collected over the whole clinical course in all patients. There were no discernible differences in viral loads or detection rates when comparing naso- and oropharyngeal swabs (Fig. 1b). The earliest swabs were taken on day 1 of symptoms, which were often very mild or prodromal. All swabs from all patients taken between day 1 and day 5 tested positive. The average virus RNA load was 6.76 × 10⁵ copies per whole swab until day 5, and the maximum load was 7.11 × 10⁸ copies per swab. Swab samples taken after day 5 had an average viral load of 3.44 × 10⁵ copies per swab and

Table 1 | Single-nucleotide polymorphism at genome position 6446 in clinical samples from patient no. 4

	Day after onset of symptoms						
	5	6	7	8	9	10	11
Swab	A		A				
Sputum		G	G	G	G>A		
Stool			G>A	A=G	A=G	G>A	A

a detection rate of 39.93%. The last swab sample that tested positive was taken on day 28 after the onset of symptoms. The average viral load in sputum was 7.00 × 10⁶ copies per ml, with a maximum of 2.35 × 10⁹ copies per ml.

Because swab samples had limited sensitivity for the initial diagnosis of cases of SARS^{13,14}, we analysed the first paired swab and sputum samples taken on the same occasion from seven patients. All samples were taken between 2 and 4 days after the onset of symptoms. In two cases, swab samples had virus concentrations that were clearly higher than those in sputum samples, as indicated by a difference of >3 in the threshold cycle (C_t) value. The opposite was true in two other cases, and the remaining three cases had similar concentrations in both sample types.

None of 27 urine samples and none of 31 serum samples tested positive for RNA from SARS-CoV2.

To understand infectivity, we attempted live virus isolation on multiple occasions from clinical samples (Fig. 1d). Whereas the virus was readily isolated during the first week of symptoms from a considerable fraction of samples (16.66% of swabs and 83.33% of sputum samples), no isolates were obtained from samples taken after day 8 in spite of ongoing high viral loads.

Virus isolation from stool samples was never successful, irrespective of viral RNA concentration, on the basis of a total of 13 samples taken between day 6 and day 12 from 4 patients. The success of virus isolation also depended on viral load: samples that contained <10⁶ copies per ml (or copies per sample) never yielded an isolate. For swab and sputum samples, interpolation based on a probit model was done to obtain laboratory-based infectivity criteria for the discharge of patients (Fig. 1e, f).

High viral loads and successful isolation from early throat swabs suggested potential virus replication in tissues of the upper respiratory tract. To obtain proof of active virus replication in the absence of histopathology, we conducted RT–PCR tests to identify viral subgenomic mRNAs directly in clinical samples (Extended Data Fig. 1). Viral subgenomic mRNA is transcribed only in infected cells and is not packaged into virions, and therefore indicates the presence of actively infected cells in samples. Levels of viral subgenomic mRNA were compared against viral genomic RNA in the same sample. In sputum samples taken on day 4 to day 9, during which time active replication in sputum was obvious in all patients as per longitudinal viral load courses (as described in ‘Viral load, antibody response and clinical course’), the ratios of mean normalized subgenomic mRNA per genome were about 0.4% (Fig. 1g). A decline occurred from day 10 to day 11. In throat swabs, all samples taken up to day 5 were in the same range, whereas no subgenomic mRNA was detectable in swabs thereafter. Together, these data indicate the active replication of SARS-CoV-2 in the throat during the first five days after the onset of symptoms. No (or only minimal) indications of replication in stool were obtained by the same method (Fig. 1g).

During our study, we sequenced full virus genomes from all patients. A G6446A exchange was first detected in one patient, and later transmitted to other patients in the cluster¹¹. In the first patient, this mutation was found in a throat swab while a sputum sample from the same day showed the original allele (G6446). The single-nucleotide




Fig. 2 | Viral load kinetics, seroconversion and clinical observations in individual cases. a–i, The panels correspond to patients no. 1 (a), 2 (b), 3 (c), 4 (d), 7 (e), 8 (f), 10 (g), 14 (h) and 16 (i) in a previous publication¹¹. Dotted lines,

limit of quantification. Experiments were performed in duplicate and the data presented are the mean of results obtained by two laboratories independently. PRNT₉₀, serum dilution that causes viral plaque reduction of 90%.

polymorphism was analysed by RT-PCR and Sanger sequencing in all sequential samples available from that patient (Table 1). The presence of separate genotypes in throat swabs and sputum strongly supported our suspicion of independent virus replication in the throat, rather than passive shedding to the throat from the lung.

Viral load, antibody response and clinical course

Daily measurements of viral load in sputum, pharyngeal swabs and stool are summarized in Fig. 2. In general, the concentrations of viral RNA were very high in initial samples. In all patients except one, the concentration of viral RNA in throat swabs seemed to be already on the decline at the time of first presentation. Viral RNA concentrations in sputum declined more slowly, with a peak during the first week of symptoms in three out of eight patients. Viral RNA concentrations in stools were also high. In many cases, the course of viral RNA concentration in stools seemed to reflect the course in sputum (Fig. 2a–c). In only one case did independent replication in the intestinal tract seem obvious from the course of stool RNA excretion (Fig. 2d). Whereas symptoms mostly waned until the end of the first week (Table 2), viral RNA remained detectable in throat swabs well into the second week. Stool and sputum samples remained RNA-positive over three weeks in six of the nine patients, in spite of full resolution of symptoms.

All cases had comparatively mild courses (Table 2). The two patients who showed some signs of lung infection were the only cases in which sputum viral loads showed a late and high peak around day 10 or 11, whereas sputum viral loads were on the decline by this time in all other patients (Fig. 2f, g). Of note, four out of nine patients showed a loss of taste and olfactory sensation, and described this loss to be stronger and more long-lasting than in common cold diseases.

Seroconversion was detected by IgG and IgM immunofluorescence using cells that express the spike protein of SARS-CoV-2 and a virus neutralization assay using SARS-CoV-2 (Table 3, Extended Data Fig. 2). Seroconversion in 50% of patients occurred by day 7, and in all patients by day 14 (Fig. 1d). No viruses were isolated after day 7. All patients showed detectable neutralizing antibodies, the titres of which did not suggest close correlation with clinical courses. Of note, patient no. 4, who showed the lowest virus neutralization titre at end of week 2, seemed to shed virus from stool over a prolonged time (Fig. 2d). Results from the differential recombinant immunofluorescence assay indicated cross-reactivity or cross-stimulation against the four endemic human coronaviruses in several patients (Extended Data Table 1).

Conclusions

The clinical courses in the patients under study—all of whom were young- to middle-aged professionals without notable underlying disease—were mild. Apart from one patient, all cases were first tested when symptoms were still mild or in the prodromal stage (a period in which most patients would present once there is general awareness of a circulating pandemic disease⁵). Diagnostic testing suggests that simple throat swabs will provide sufficient sensitivity at this stage of infection. This is in stark contrast to SARS; for instance, only 38 of 98 nasal or nasopharyngeal swab samples tested positive by RT-PCR in patients with SARS in Hong Kong¹⁵. Viral load also differs considerably between SARS and COVID-19. For SARS, it took 7 to 10 days after the onset of symptoms until peak RNA concentrations (of up to 5×10^5 copies per swab) were reached^{13,14}. In the present study, peak concentrations were reached before day 5, and were more than 1,000 times higher. Successful isolation of live virus from throat swabs is another notable difference between COVID-19 and SARS, for which such isolation was

Table 2 | Clinical characteristics of all patients

Patient ID no.	Comorbidity	Initial symptoms	Later symptoms	ANC per μ l	ALC per μ l	CRP (mg l ⁻¹)	LDH (U l ⁻¹)
1	Hypothyroidism	Cough, fever, diarrhoea	Diarrhoea	4,870	1,900	46	197
2	None	Sinusitis, cephalgia, cough	Hyposmia, ageusia	3,040	1,200	4.9	182
3	COPD	Arthralgia, sinusitis, cough	Dysosmia, dysgeusia	5,040	2,600	1.3	191
4	None	Otitis, rhinitis	Hyposmia, hypogeusia	2,420	2,220	5.9	149
7	Hypercholesterolaemia	Rhinitis, cough	Fever, dyspnoea, hyposmia, hypogeusia	4,690	900	4.9	209
8	None	Sinusitis, cough		2,500	1,600	1.7	203
10	None	Sinusitis, cough	Fever, cough	2,350	700	7.8	220
14	None	Fever, cough, diarrhoea		5,040	1,500	9.8	220
16	None	None		4,620	900	0.5	201

ALC, absolute lymphocyte count; ANC, absolute neutrophil count; CRP, C-reactive protein; COPD, chronic obstructive pulmonary disease; LDH, lactate dehydrogenase.

rarely successful^{16–18}. This suggests active virus replication in tissues of the upper respiratory tract, where SARS-CoV is not thought to replicate in spite of detectable ACE2 expression^{19,20}. At the same time, the concurrent use of ACE2 as a receptor by SARS-CoV and SARS-CoV-2 corresponds to a highly similar excretion kinetic in sputum, with active replication in the lung. SARS-CoV was previously found¹³ in sputum at mean concentrations of $1.2\text{--}2.8 \times 10^6$ copies per ml, which corresponds to observations made here.

Whereas proof of replication by histopathology is awaited, extended tissue tropism of SARS-CoV-2 with replication in the throat is strongly supported by our studies of cells that transcribe subgenomic mRNA in throat swab samples, particularly during the first 5 days of symptoms. Notable additional evidence for independent replication in the throat is provided by sequence findings in one patient, who consistently showed a distinct virus in the throat as opposed to the lung. In addition, the disturbance of gustatory and olfactory senses points at an infection of the tissues of the upper respiratory tract.

Critically, the majority of patients in the present study seemed to be beyond their shedding peak in samples from the upper respiratory tract when they were first tested, whereas the shedding of infectious virus in sputum continued throughout the first week of symptoms. Together, these findings suggest a more efficient transmission of SARS-CoV-2 than SARS-CoV, through active pharyngeal viral shedding at a time at which symptoms are still mild and typical of infections of the upper respiratory tract. Later in the disease, COVID-19 resembles SARS in terms of replication in the lower respiratory tract. Of note, the two patients who showed some symptoms of the lungs being affected showed a

prolonged viral load in sputum. Our study is limited, in that no severe cases were observed. Future studies that include severe cases should look at the prognostic value of an increase of viral load beyond the end of week 1, potentially indicating an aggravation of symptoms.

One of the most interesting hypotheses to explain the potential extension of tropism to the throat is the presence of a polybasic furin-type cleavage site at the S1–S2 junction in the SARS-CoV-2 spike protein that is not present in SARS-CoV¹⁷. The insertion of a polybasic cleavage site in the S1–S2 region in SARS-CoV has previously been shown to lead to a moderate, but discernible, gain-of-fusion activity that might result in increased viral entry in tissues with a low density of ACE2 expression²¹.

The combination of very high concentrations of virus RNA and the occasional detection of cells in stools that contain subgenomic mRNA indicate active replication in the gastrointestinal tract. Active replication is also suggested by a much higher detection rate compared to the Middle East respiratory system coronavirus (MERS-CoV), for which stool-associated RNA was found in only 14.6% of samples from 37 patients hospitalized in Riyadh (Saudi Arabia)^{22,23}. If SARS-CoV-2 was only passively present in the stool (such as after swallowing respiratory secretions), similar detection rates as for MERS-CoV would be expected. Replication in the gastrointestinal tract is also supported by analogy with SARS-CoV, which was regularly excreted in stool (from which it could be isolated in cell culture²⁴). Our failure to isolate live SARS-CoV-2 from stools may be due to the mild courses of cases, with only one case showing intermittent diarrhoea. In China, diarrhoea was seen in only 2 of 99 cases²⁵. Further studies should therefore address whether SARS-CoV-2 shed in stools is rendered noninfectious though contact with the gut environment. Our initial results suggest that measures to contain viral spread should aim at droplet-, rather than fomite-, based transmission.

The prolonged viral shedding in sputum is relevant not only for the control of infections in hospitals, but also for discharge management. In a situation characterized by a limited capacity of hospital beds in infectious disease wards, there is pressure for early discharge after treatment. On the basis of the present findings, early discharge with ensuing home isolation could be chosen for patients who are beyond day 10 of symptoms and have less than 100,000 viral RNA copies per ml of sputum. Both criteria predict that there is little residual risk of infectivity, on the basis of cell culture.

The serological courses of all patients suggest a timing of seroconversion similar to, or slightly earlier than, in SARS-CoV infection¹⁸. Seroconversion in most cases of SARS occurred during the second week of symptoms. As in SARS and MERS, IgM was not detected considerably earlier than IgG in immunofluorescence; this might in part be due to technical reasons, as the higher avidity of IgG antibodies outcompetes IgM for viral epitopes in the assay. IgG depletion can only partially alleviate this effect. Because immunofluorescence assay is a

Table 3 | IgG and IgM immunofluorescence titres against SARS-CoV-2, from all patients

Patient ID no.	Initial serum		Final serum				
	Day after onset	IgG	Day after onset	IgG	IgM	PRNT ₉₀	PRNT ₅₀
1	5	<10	21	1,000	100	160	>640
2	4	<10	19	1,000	100	40	320
3	3	<10	23	1,000	100	160	>640
4	5	<10	17	10,000	<10	20	160
7	6	<10	20	10,000	100	>1,280	>1,280
8	6	10	20	10,000	10	80	>320
10	6	<10	28	1,000	10	10	>40
14	NA	NA	12	10,000	100	>40	>40
16	NA	NA	13	1,000	100	80	>320

NA, not applicable; PRNT₅₀, serum dilution that causes viral plaque reduction of 50%.

labour-intensive method, enzyme-linked immunosorbent assay tests should be developed as a screening test. Neutralization testing is necessary to rule out cross-reactive antibodies directed against endemic human coronaviruses. On the basis of the frequently low neutralizing antibody titres observed in coronavirus infection^{26,27}, we have here developed a particularly sensitive plaque-reduction neutralization assay. Considering the titres we observed, a simpler microneutralization test format is likely to provide sufficient sensitivity in routine application and population studies.

When aligned to viral load courses, it seems there is no abrupt virus elimination at the time of seroconversion. Rather, seroconversion early in week 2 coincides with a slow but steady decline of viral load in sputum. Whether properties such as the glycosylation pattern at critical sites of the glycoprotein have a role in the attenuation of the neutralizing antibody response needs further clarification. In any case, vaccine approaches targeting mainly the induction of antibody responses should aim to induce particularly strong antibody responses to be effective.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-020-2196-x>.

1. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl. J. Med.* **382**, 727–733 (2020).
2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species *Severe acute respiratory syndrome-related coronavirus*: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat. Microbiol.* **5**, 536–544 (2020).
3. WHO. Report of the WHO–China Joint Mission on Coronavirus Disease 2019 (COVID-19) <https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf> (WHO, 2020).
4. Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* **181**, 271–280 (2020).
5. Leung, G. M. et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. *Ann. Intern. Med.* **141**, 662–673 (2004).
6. Rothe, C. et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. *N. Engl. J. Med.* **382**, 970–971 (2020).
7. Holshue, M. L. et al. First case of 2019 novel coronavirus in the United States. *N. Engl. J. Med.* **382**, 929–936 (2020).
8. Hoehl, S. et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. *N. Engl. J. Med.* **382**, 1278–1280 (2020).
9. Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N. Engl. J. Med.* **382**, 1177–1179 (2020).
10. Young, B. E. et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. *J. Am. Med. Assoc.* **323**, 1488–1494 (2020).
11. Böhrer, M. et al. Outbreak of COVID-19 in Germany resulting from a single travel-associated primary case. *Lancet Infect. Dis.* [https://doi.org/10.1016/S1473-3099\(20\)30314-5](https://doi.org/10.1016/S1473-3099(20)30314-5) (2020).
12. Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill.* **25**, 1–8 (2020).
13. Drosten, C. et al. Evaluation of advanced reverse transcription-PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome-associated coronavirus. *J. Clin. Microbiol.* **42**, 2043–2047 (2004).
14. Peiris, J. S. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet* **361**, 1767–1772 (2003).
15. Poon, L. L. et al. Detection of SARS coronavirus in patients with severe acute respiratory syndrome by conventional and real-time quantitative reverse transcription-PCR assays. *Clin. Chem.* **50**, 67–72 (2004).
16. Ksiazek, T. G. et al. A novel coronavirus associated with severe acute respiratory syndrome. *N. Engl. J. Med.* **348**, 1953–1966 (2003).
17. Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N. Engl. J. Med.* **348**, 1967–1976 (2003).
18. Peiris, J. S. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet* **361**, 1319–1325 (2003).
19. Bertram, S. et al. Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. *PLoS ONE* **7**, e35876 (2012).
20. Xu, H. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int. J. Oral Sci.* **12**, 8 (2020).
21. Belouzard, S., Chu, V. C. & Whittaker, G. R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. *Proc. Natl Acad. Sci. USA* **106**, 5871–5876 (2009).
22. Corman, V. M. et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. *Clin. Infect. Dis.* **62**, 477–483 (2016).
23. Zhou, J. et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. *Sci. Adv.* **3**, eaao4966 (2017).
24. Leung, W. K. et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. *Gastroenterology* **125**, 1011–1017 (2003).
25. Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507–513 (2020).
26. Drosten, C. et al. Transmission of MERS-coronavirus in household contacts. *N. Engl. J. Med.* **371**, 828–835 (2014).
27. Müller, M. A. et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. *Lancet Infect. Dis.* **15**, 559–564 (2015).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature Limited 2020

Article

Methods

No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment.

Clinical samples and viral load conversion

Sputum and stool samples were taken and shipped in native conditions. Oro- and nasopharyngeal throat swabs were preserved in 3 ml of viral transport medium. Viral loads in sputum samples were projected to RNA copies per ml, in stool samples to copies per g and in throat swabs to copies per 3 ml, assuming that all sample components were suspended in 3 ml viral transport medium. For swab samples suspended in less than 3 ml viral transport medium, this conversion was adapted to represent copies per whole swab. An aggregated overview of samples received per day after the onset of disease from all patients is shown in Fig. 1a.

RT-PCR for SARS-CoV-2 and other respiratory viruses

RT-PCR used targets in the *E* and *RdRp* genes as previously described¹². Both laboratories used a pre-formulated oligonucleotide mixture (Tib-Molbiol) to make the laboratory procedures more reproducible. All patients were also tested for other respiratory viruses, including HCoV-HKU1, HCoV-OC43, HCoV-NL63 and HCoV-229E, influenza virus A, influenza virus B, rhinovirus, enterovirus, respiratory syncytial virus, human parainfluenza viruses 1–4, human metapneumovirus, adenovirus and human bocavirus using LightMix-Modular Assays (Roche). Additional technical details are provided in Supplementary Methods section 1.

Virus isolation

Virus isolation was done in two laboratories on Vero E6 cells. In brief, 100 µl of suspended, cleared and filtered clinical sample was mixed with an equal volume of cell culture medium. Supernatant was collected after 0, 1, 3 and 5 days and used in RT-PCR analysis. Additional technical details are provided in Supplementary Methods section 2a.

Serology

We performed recombinant immunofluorescence assays to determine the specific reactivity against recombinant spike proteins in VeroB4 cells, as previously described^{26,28}. This assay used a cloned coronavirus spike protein from HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1 or SARS-CoV-2. The screening dilution was 1:10. Plaque reduction neutralization tests were done essentially as previously described for MERS-CoV²⁶. Serum dilutions causing plaque reductions of 90% (PRNT₉₀) and 50% (PRNT₅₀) were recorded as titres. Additional technical details are provided in Supplementary Methods section 2b, c.

Statistical analyses

Statistical analyses were done using SPSS software (version 25) or GraphPad Prism (version 8).

Ethical approval statement

All patients provided informed consent for the use of their data and clinical samples for the purposes of the present study. Institutional review board clearance for the scientific use of patient data has been granted to the treating institution by the ethics committee at the Medical Faculty of the Ludwig Maximilians Universität Munich (vote 20-225 KB).

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

Data availability

Sequence data are available in GISAID under accession number EPI_ISL_406862. All other data are available from C.D. upon reasonable request.

28. Corman, V. M. et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. *Euro Surveill.* **17**, 20334 (2012).

Acknowledgements This work was funded by grants from the German Ministry of Research (01K11723A) and the European Union (602525) to C.D. as well as by the German Bundeswehr Medical Service Biodefense Research Program. The funders had no role in study design, data collection and analysis or decision to publish. We thank P. Mackeldanz, E. Möncke-Buchner, A. Richter, M. Schmidt and J. Beheim-Schwarzbach for technical assistance.

Author contributions R.W. and V.M.C. planned and supervised laboratory testing, and evaluated data. W.G. and M.S. managed patients and evaluated clinical data. S.Z., T.B., S.B., J.S., R.E. and K.Z. performed laboratory testing. M.A.M. managed serological laboratory testing. D.N. managed and performed virus isolation studies. T.C.J. analysed sequences and population-specific polymorphisms. P.V. managed laboratory testing. C.R. managed initial patient contacts. M.H. managed initial patient contacts and evaluated clinical data. C.D. designed and supervised laboratory studies, and wrote the manuscript. C.W. designed and supervised clinical management and clinical data.

Competing interests The authors declare no competing interests.


Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41586-020-2196-x>.


Correspondence and requests for materials should be addressed to C.D. or C.W.

Peer review information Nature thanks Peter Openshaw and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at <http://www.nature.com/reprints>.



Extended Data Fig. 1 | Sequence analysis of *E* gene subgenomic mRNA. The leader sequence (purple), putative transcription regulatory sequences (TRS) (grey) and nucleotides coding for the 5'-proximal part of the *E* gene (yellow box) are shown. PCR primer binding sites used for amplification and RT-PCR detection are shown as green arrows, and the 5'-nuclease PCR probe is shown as a red arrow.



Extended Data Fig. 2 | Recombinant SARS-CoV-2-spike-based immunofluorescence test shows seroconversion of patient no. 4.

Representative outcome of a recombinant immunofluorescence test using serum dilutions 1:10, 1:100, 1:1,000 and 1:10,000 of patient no. 4 at 5 and 17 days

after the onset of symptoms. Secondary detection was done by using a goat-anti human immunoglobulin labelled with Alexa Fluor 488 (shown in green). The experiment was performed in duplicate.

Extended Data Table 1 | IgG immunofluorescence titres against endemic human coronaviruses

Patient ID	<i>Primary serum</i>					<i>Final serum</i>				
	Day p.o.	OC43	NL63	HKU1	229E	Day p.o.	OC43	NL63	HKU1	229E
#1	5	1,000	1,000	1,000	100	15	1,000	1,000	1,000	100
#2	4	1,000	1,000	100	100	13	10,000	100	1,000	10
#3	3	10,000	100	1,000	1000	16	10,000	1,000	10,000	1,000
#4	5	1,000	100	100	100	17	10,000	10	1,000	100
#7	6	1,000	100	1,000	1000	13	10,000	1,000	10,000	10,000
#8	6	1,000	100	1,000	1000	10	10,000	1,000	10,000	100
#10	6	1,000	100	100	1000	11	10,000	1,000	100	1,000
#14	na	na	na	na	na	5	100	100	100	100
#16	na	na	na	na	na	13	10,000	1,000	1,000	100

p.o., post onset; na, not available. Increases of titre through the final serum are indicated by reciprocal titres in bold.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Microsoft Excel,

Data analysis

SPSS, GraphPad Prism, Geneious

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data upon which figures and conclusions are based can be obtained from the corresponding author upon reasonable request. These data cannot be published in an open source because their interpretation may affect aspects of patient privacy.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Nine Patients.
Data exclusions	None.
Replication	Testing by two different laboratories.
Randomization	None.
Blinding	None.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involvement in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data

Methods

n/a	Involvement in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used	Secondary anti-human IgG reagents (Euroimmun).
Validation	Immunofluorescence.

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	In-house collection with reference to ATCC or DSZM.
Authentication	Functional testing for IFN locus inactivation.
Mycoplasma contamination	Regular testing.
Commonly misidentified lines (See ICLAC register)	N/A

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	N.A.
Recruitment	Clinical admission due to symptoms, contact history, and positive initial test.
Ethics oversight	Research ethics board of Ludwig Maximilians University Munich; informed consent to scientific use and publication of anonymized data by each patient.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	N.A.
Study protocol	No study protocol emergency admissions of patients with new disease.
Data collection	Data collection at treating hospital, and two laboratories as identified in affiliations list.
Outcomes	Laboratory and clinical status. No explicit outcome measure.